J Gastric Cancer.  2018 Sep;18(3):264-273. 10.5230/jgc.2018.18.e29.

Who Can Perform Adjuvant Chemotherapy Treatment for Gastric Cancer? A Multicenter Retrospective Overview of the Current Status in Korea

  • 1Department of Surgery, Dongnam Institute of Radiological and Medical Sciences, Cancer Center, Busan, Korea.
  • 2Department of Surgery, Korea University Medical Center, Korea University College of Medicine, Seoul, Korea. kugspss@korea.ac.kr
  • 3Department of Surgery, Kyung Hee University Hospital at Gangdong, Seoul, Korea.
  • 4Department of Surgery, Kosin University College of Medicine, Busan, Korea.
  • 5Department of Surgery, Seoul National University Bundang Hospital, Seongnam, Korea.
  • 6Department of Surgery, Dongguk University Hospital, Goyang, Korea.
  • 7Department of Surgery, Soonchunhyang University Cheonan Hospital, Cheonan, Korea.
  • 8Department of Surgery, Hallym University Kangdong Sacred Heart Hospital, Seoul, Korea.
  • 9Department of Surgery, Chosun University College of Medicine, Gwangju, Korea.
  • 10Department of Surgery, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea.
  • 11Department of Surgery, Hanyang University Guri Hospital, Guri, Korea.
  • 12Department of Surgery, Chung-Ang University College of Medicine, Seoul, Korea.
  • 13Department of Surgery, Gyeongsang National University Hospital, Changwon, Korea.
  • 14Department of Surgery, Eulji University Hospital, Daejeon, Korea.


To investigate the current status of adjuvant chemotherapy (AC) regimens in Korea and the difference in efficacy of AC administered by surgical and medical oncologists in patients with stage II or III gastric cancers.
We performed a retrospective observational study among 1,049 patients who underwent curative resection and received AC for stage II and III gastric cancers between February 2012 and December 2013 at 29 tertiary referral university hospitals in Korea. To minimize the influence of potential confounders on selection bias, propensity score matching (PSM) was used based on binary logistic regression analysis. The 3-year disease-free survival (DFS) rates were compared between patients who received AC administered by medical oncologists or surgical oncologists.
Between February 2012 and December 2013 in Korea, the most commonly prescribed AC by medical oncologists was tegafur/gimeracil/oteracil (S-1, 47.72%), followed by capecitabine with oxaliplatin (XELOX, 16.33%). After performing PSM, surgical oncologists (82.74%) completed AC as planned more often than medical oncologists (75.9%), with statistical significance (P=0.036). No difference in the 3-year DFS rates of stage II (P=0.567) or stage III (P=0.545) gastric cancer was found between the medical and surgical oncologist groups.
S-1 monotherapy and XELOX are a main stay of AC, regardless of whether the prescribing physician is a medical or surgical oncologist. The better compliance with AC by surgical oncologists is a valid reason to advocate that surgical oncologists perform the treatment of AC for stage II or III gastric cancers.


Gastric cancer; Adjuvant chemotherapy

MeSH Terms

Chemotherapy, Adjuvant*
Disease-Free Survival
Hospitals, University
Logistic Models
Observational Study
Propensity Score
Referral and Consultation
Retrospective Studies*
Selection Bias
Stomach Neoplasms*
Full Text Links
  • JGC
export Copy
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error